Mike leads a team of experts representing innovative research-based biopharmaceutical companies pioneering an exciting new era of biosciences in the UK. The pharmaceutical industry, a major contributor to the economy, brings life-saving and life-enhancing medicines to patients. Globally the industry is researching and developing more than 7,000 new medicines. Mike and his team represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is also recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
Mike joined the ABPI from GlaxoSmithKline where he was most recently senior vice president for global commercial strategy and platforms. A graduate of The Queen's College, Oxford, Mike has worked across multiple sectors including food, drinks, toiletries and Government agencies.